Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.32 |
| ▸ | USP19 | O94966 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25923944 | 0.93 | TSHR (0.35) | LMNATSHRUSP2ALDH1A1EPHX2 | |
| SCHEMBL25884460 | 0.89 | LMNA (0.37) | LMNATSHRUSP2ALDH1A1EPHX2 | |
| SCHEMBL23945776 | 0.89 | LMNA (0.37) | LMNATSHRUSP2ALDH1A1EPHX2 | |
| SCHEMBL25480360 | 0.88 | USP2 (0.41) | LMNATSHRUSP2ALDH1A1EPHX2 | |
| SCHEMBL25707635 | 0.88 | LMNA (0.37) | LMNATSHRUSP2ALDH1A1EPHX2 | |
| SCHEMBL25707706 | 0.87 | USP2 (0.43) | LMNATSHRUSP2ALDH1A1EPHX2 | |
| SCHEMBL26405356 | 0.86 | USP2 (0.38) | LMNATSHRUSP2ALDH1A1EPHX2 | |
| SCHEMBL25887966 | 0.86 | TSHR (0.38) | LMNATSHRUSP2ALDH1A1EPHX2 | |
| SCHEMBL25928060 | 0.86 | TSHR (0.37) | LMNATSHRUSP2ALDH1A1EPHX2 | |
| SCHEMBL23807008 | 0.85 | CYP2C19 (0.37) | LMNATSHRUSP2ALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | LMNA 1656/4885TSHR 3319/4885USP2 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.